
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| respiratory tract diseases | D012140 |
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Imfinzi | durvalumab | AstraZeneca | N-761069 RX | 2017-05-01 | 2 products |
Brand Name | Status | Last Update |
|---|---|---|
| imfinzi | Biologic Licensing Application | 2025-03-28 |
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| transitional cell carcinoma | — | D002295 | — |
Expiration | Code | ||
|---|---|---|---|
durvalumab, Imfinzi, AstraZeneca UK Ltd | |||
| 2029-10-21 | Orphan excl. | ||
Code | Description |
|---|---|
| J9173 | Injection, durvalumab, 10 mg |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 20 | 52 | 22 | 2 | 11 | 102 |
| Lung neoplasms | D008175 | — | C34.90 | 16 | 47 | 6 | 1 | 3 | 67 |
| Neoplasms | D009369 | — | C80 | 19 | 17 | 2 | 1 | — | 36 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 16 | 31 | 8 | — | 2 | 50 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 17 | 27 | 3 | — | — | 38 |
| Small cell lung carcinoma | D055752 | — | — | 8 | 16 | 7 | — | 4 | 34 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 6 | 13 | 6 | — | 4 | 26 |
| Urinary bladder neoplasms | D001749 | — | C67 | 7 | 16 | 4 | — | — | 25 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 6 | 11 | 6 | — | 2 | 23 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 12 | 13 | 1 | — | — | 22 |
| Squamous cell carcinoma | D002294 | — | — | 12 | 14 | 1 | — | — | 22 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 9 | 12 | 1 | — | — | 18 |
| Biliary tract neoplasms | D001661 | — | C24.9 | 2 | 5 | 4 | — | 3 | 14 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 8 | 15 | — | — | — | 20 |
| Triple negative breast neoplasms | D064726 | — | — | 9 | 13 | — | — | — | 19 |
| Adenocarcinoma | D000230 | — | — | 6 | 17 | — | — | — | 18 |
| Colorectal neoplasms | D015179 | — | — | 8 | 10 | — | — | — | 16 |
| Cholangiocarcinoma | D018281 | — | C22.1 | — | 9 | — | — | — | 9 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 5 | 5 | — | — | — | 8 |
| Esophageal neoplasms | D004938 | — | C15 | 3 | 6 | — | — | — | 8 |
| Prostatic neoplasms | D011471 | — | C61 | 2 | 6 | — | — | — | 7 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 4 | 5 | — | — | — | 7 |
| Melanoma | D008545 | — | — | 5 | 2 | — | — | — | 6 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| B-cell lymphoma | D016393 | — | — | 2 | — | — | — | — | 2 |
| Thyroid neoplasms | D013964 | EFO_0003841 | — | 2 | — | — | — | — | 2 |
| Second primary neoplasms | D016609 | — | — | 1 | — | — | — | — | 1 |
| Male breast neoplasms | D018567 | — | — | 1 | — | — | — | — | 1 |
| Vaginal neoplasms | D014625 | — | C52 | 1 | — | — | — | — | 1 |
| Vulvar neoplasms | D014846 | — | C51 | 1 | — | — | — | — | 1 |
| Anaplastic thyroid carcinoma | D065646 | — | — | 1 | — | — | — | — | 1 |
| Thyroid diseases | D013959 | — | E00-E07 | 1 | — | — | — | — | 1 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | — | — | — | — | 1 |
| Pharyngeal neoplasms | D010610 | — | C14.0 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hereditary sensory and autonomic neuropathies | D009477 | — | — | — | — | — | — | 1 | 1 |
| Drug common name | Durvalumab |
| INN | durvalumab |
| Description | Durvalumab (human mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | >5X8M:B|durvalumab heavy chain
EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLY
LQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTV
SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTHHHHHH
>5X8M:C|durvalumab light chain
EIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLE
PEDFAVYYCQQYGSLPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS
QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
| PDB | 5X8M, 5XJ4 |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL3301587 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB11714 |
| UNII ID | 28X28X9OKV (ChemIDplus, GSRS) |



